scholarly journals Drug-Induced QT Interval Prolongation

2021 ◽  
Vol 1 (2) ◽  
Author(s):  
Domina Petric
Keyword(s):  
Qt Interval ◽  
Qt Prolongation ◽  
Database Search ◽  
Confirmatory Test ◽  
Correct Interpretation ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qt Interval Prolongation ◽  
Common Causes ◽  
Clinical Consequences

The correct measurement of the QT interval (using the QT correction formulas, preferably Fridericia and Framingham) as well as a correct interpretation of the causes and of the clinical consequences of a QT prolongation is very important in clinical practice. Drug-induced long QT syndrome (DILQTS) is one of the most common causes of LQTS. In the diagnosis and management of the DILQTS, it can be useful to follow the three-step rule presented in this article: detailed pharmacological anamnesis and correct ECG interpretation; database search and clinical interpretation; confirmatory test.

scholarly journals Papaverine-induced QT Interval Prolongation and Ventricular Fibrillation in a Patient with a History of Drug-induced QT Prolongation

2014 ◽  
Vol 53 (15) ◽  
pp. 1629-1631 ◽  
Author(s):  
Masayuki Goto ◽  
Masahito Sato ◽  
Hitoshi Kitazawa ◽  
Minoru Takahashi ◽  
Koichi Fuse ◽  
...  
Keyword(s):  
Ventricular Fibrillation ◽  
Qt Interval ◽  
Qt Prolongation ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qt Interval Prolongation ◽  
History Of

scholarly journals A Comparative Study of Rat Urine 1H-NMR Metabolome Changes Presumably Arising from Isoproterenol-Induced Heart Necrosis Versus Clarithromycin-Induced QT Interval Prolongation

Biology ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 98
Author(s):  
Matthieu Dallons ◽  
Manon Delcourt ◽  
Corentin Schepkens ◽  
Manuel Podrecca ◽  
Jean-Marie Colet
Keyword(s):  
Drug Development ◽  
1H Nmr ◽  
Qt Interval ◽  
Krebs Cycle ◽  
Predictive Biomarkers ◽  
Qt Prolongation ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qt Interval Prolongation ◽  
Krebs Cycle Intermediates

Cardiotoxicity remains a challenging concern both in drug development and in the management of various clinical situations. There are a lot of examples of drugs withdrawn from the market or stopped during clinical trials due to unpredicted cardiac adverse events. Obviously, current conventional methods for cardiotoxicity assessment suffer from a lack of predictivity and sensitivity. Therefore, there is a need for developing new tools to better identify and characterize any cardiotoxicity that can occur during the pre-clinical and clinical phases of drug development as well as after marketing in exposed patients. In this study, isoproterenol and clarithromycin were used as prototypical cardiotoxic agents in rats in order to evaluate potential biomarkers of heart toxicity at very early stages using 1H-NMR-based metabonomics. While isoproterenol is known to cause heart necrosis, clarithromycin may induce QT interval prolongation. Heart necrosis and QT prolongation were validated by histological analysis, serum measurement of lactate dehydrogenase/creatine phosphate kinase and QTc measurement by electrocardiogram (ECG). Urine samples were collected before and repeatedly during daily exposure to the drugs for 1H-NMR based-metabonomics investigations. Specific metabolic signatures, characteristic of each tested drug, were obtained from which potential predictive biomarkers for drug-induced heart necrosis and drug-induced QT prolongation were retrieved. Isoproterenol-induced heart necrosis was characterized by higher levels of taurine, creatine, glucose and by lower levels of Krebs cycle intermediates, creatinine, betaine/trimethylamine N-oxide (TMAO), dimethylamine (DMA)/sarcosine. Clarithromycin-induced QT prolongation was characterized by higher levels of creatinine, taurine, betaine/TMAO and DMA/sarcosine and by lower levels of Krebs cycle intermediates, glucose and hippurate.

scholarly journals Drug-induced QT interval prolongation in cancer patients

2011 ◽  
Vol 4 (4) ◽  
pp. 223
Author(s):  
Torben K. Becker ◽  
Sai-Ching J. Yeung
Keyword(s):  
Cancer Patients ◽  
Qt Interval ◽  
Alkylating Agents ◽  
Torsade De Pointes ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Vascular Disruption ◽  
Qt Interval Prolongation ◽  
Increased Risk ◽  
Multiple Drugs

Cancer patients are at an increased risk for QT interval prolongation and subsequent potentially fatal Torsade de pointes tachycardia due to the multiple drugs used for treatment of malignancies and the associated symptoms and complications. Based on a systematic review of the literature, this article analyzes the risk for prolongation of the QT interval with antineoplastic agents and commonly used concomitant drugs. This includes anthracyclines, fluorouracil, alkylating agents, and new molecularly targeted therapeutics, such as vascular disruption agents. Medications used in the supportive care can also prolong QT intervals, such as methadone, 5-HT3-antagonists and antihistamines, some antibiotics, antifungals, and antivirals. We describe the presumed mechanism of QT interval prolongation, drug-specific considerations, as well as important clinical interactions. Multiple risk factors and drug–drug interactions increase this risk for dangerous arrhythmias. We propose a systematic approach to evaluate cancer patients for the risk of QT interval prolongation and how to prevent adverse effects.

Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities

2015 ◽  
Vol 42 (6) ◽  
pp. 659-679 ◽  
Author(s):  
Eleonora Marostica ◽  
Karel Van Ammel ◽  
Ard Teisman ◽  
Koen Boussery ◽  
Jan Van Bocxlaer ◽  
...  
Keyword(s):  
Qt Interval ◽  
Interval Prolongation ◽  
Drug Induced ◽  
Qt Interval Prolongation
Sign in / Sign up

Export Citation Format

Share Document